<DOC>
	<DOCNO>NCT00884312</DOCNO>
	<brief_summary>This multi-center , open-label , Phase 2 study carfilzomib monitor safety efficacy long-term continue carfilzomib therapy subject previously complete primary carfilzomib treatment study . Only subject adequately complete prior carfilzomib study eligible current study .</brief_summary>
	<brief_title>A Study Extended Carfilzomib Therapy Subjects Previously Enrolled Carfilzomib Treatment Protocols</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>1 . Previous completion carfilzomib study within 90 day prior first dose maintenance study drug . 2 . Disease Assessments perform within 30 day prior first dose maintenance study drug . 3 . Written inform consent accordance federal , local , institutional guideline 4 . Females childbearing potential ( FCBP ) * must negative serum urine pregnancy test , sensitivity least 50 mIU/mL , within 3 day prior first dose maintenance study drug . 5 . Subjects must agree adhere study visit schedule study requirement receive outpatient treatment laboratory monitor institution administers drug . 1 . Administration intervene chemotherapy time previous carfilzomib study termination first dose maintenance study drug . 2 . Pregnant lactating female 3 . Diagnosis new malignancy different tumor type .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Multiple myeloma</keyword>
	<keyword>proteasome</keyword>
	<keyword>Hematological</keyword>
	<keyword>carfilzomib</keyword>
	<keyword>PR-171</keyword>
</DOC>